Sharps Technology, Inc. (STSSW) Stock Analysis

Company Overview

Sharps Technology, Inc. operates as a specialized provider of smart-safety syringe products within the healthcare industry, focusing on waste management capabilities that integrate advanced syringe technologies. The company functions within the medical device and pharmaceutical packaging sectors, though specific sector and industry classifications are not currently available in its public filings. In terms of operational scale, Sharps Technology, Inc. maintains an employee base of 55 individuals and reports a trailing twelve-month revenue of $306,344. The reported market capitalization is listed as N/A, and the price-to-book ratio is 0.00, which suggests the market valuation does not exceed the company's book value or that the equity structure is distinct from standard market capitalization metrics. These financial figures indicate that the company operates with a relatively small workforce and generates modest revenue, positioning it as a micro-cap entity with limited historical market data available for standard valuation comparisons. The absence of a traditional market cap figure alongside a zero price-to-book ratio often reflects companies that are either newly listed, delisted, or have unique capital structures that prevent standard valuation ratios from applying in conventional ways.

Financial Health

The company reported a revenue of $306,344 over the trailing twelve months, yet simultaneously recorded a net income of $-104,371,584 and an EBITDA of $-118,102,136. The massive disparity between the positive revenue figure and the negative net income reveals a severe cost structure issue where operating expenses and losses far exceed the gross revenue generated by the business. Despite the significant operating losses, the company maintains a free cash flow of $2.80M, which indicates a degree of financial flexibility potentially derived from asset sales or non-operational cash movements, although this positive cash flow contrasts sharply with the negative earnings. The gross margin stands at 0.0%, indicating that the cost of goods sold equals or exceeds total revenue, while the operating margin is a staggering -131347.6% and the profit margin is also 0.0%. These extreme margin figures suggest that the company is operating at a level where every dollar of revenue is insufficient to cover a fraction of its operational costs, resulting in negative profitability across all standard measures. On the balance sheet, the company holds $10.52M in cash against $7.63M in debt, resulting in a debt-to-equity ratio of 1.76, which indicates a leveraged position where debt exceeds equity. However, the current ratio of 3.74 suggests that the company possesses sufficient current assets to cover its short-term liabilities, pointing to adequate short-term liquidity despite the negative earnings. Return on Equity is -47.5% and Return on Assets is -32.6%, metrics that reveal that management effectiveness is currently negative as the company destroys shareholder value and utilizes assets to generate losses rather than returns.

Valuation Assessment

The trailing P/E ratio and forward P/E ratio are both listed as N/A, which implies that standard earnings-based valuation models cannot be applied due to the absence of positive earnings or the extreme negative income figures. The price-to-book ratio is 0.00, indicating that the market capitalization does not carry a premium over the book value of the company's assets, or that the valuation is effectively zero relative to its accounting equity. The price-to-sales ratio is also N/A, and the EV/EBITDA is N/A, suggesting that alternative valuation metrics are unavailable due to the company's negative earnings and lack of traditional market data. The stock has a 52-week high of $0.05 and a 52-week low of $0.05, meaning the current trading price sits exactly at the narrowest range of its recent trading history with no deviation from the high or low. With a beta of 2.20, the stock exhibits high price volatility, moving more than twice as much as the broader market in either direction, which increases the risk profile for holders of this asset. The lack of a forward P/E and the zero price-to-book ratio further complicate any attempt to value the stock using traditional multiples, highlighting the speculative nature of the investment.

Growth & Income

The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue. Because the company is a non-dividend payer, there is no dividend yield or payout ratio to analyze, meaning the company reinvests its limited cash flow or utilizes its cash reserves into growth initiatives rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete absence of historical growth data and a lack of dividend income, reflecting a company that is currently in a phase of significant financial distress rather than expansion or income generation. The financial data indicates that the primary focus for this entity is likely on survival and restructuring rather than delivering revenue growth, earnings growth, or dividend payments to investors.